Connect with us

Headlines

Essilor and Luxottica Iron Out Leadership Struggles

A new agreement ‘settles any existing dispute.’

mm

Published

on

CHARENTON-LE-PONT, FRANCE – A new settlement agreement addresses governance issues and sets the basis for a “renewed start of profound collaboration” between Essilor and Luxottica.

The agreement “settles any existing dispute among the parties,” which completed a merger in October to form EssilorLuxottica, according to a press release. The organization has since been plagued by infighting among its leadership.

The agreement is between EssilorLuxottica and Delfin, holding company of Leonardo Del Vecchio, the top shareholder of EssilorLuxottica. It is “aimed at immediately making the Group’s structure more efficient and effective from an operational standpoint.”

According to the agreement:

  • Del Vecchio and Hubert Sagnières, who serves as vice chairman of the merged organization, empowered Francesco Milleri (deputy chairman – CEO of Luxottica Group) and Laurent Vacherot (CEO of Essilor International) to “develop and implement the EssilorLuxottica strategy and integration process, accelerating the simplification of the new Group by integrating the two operating companies within the next 12 to 24 months.”
  • Milleri and Vacherot approved the appointment of key executives for the group’s central functions.
  • Vacherot has been appointed as a director of EssilorLuxottica, replacing Bernard Hours, who has asked to be relieved of his office. He will also become a member of the board’s strategy committee.
  • The board confirmed the search for a new CEO. Milleri and Vacherot have informed the board that they are not candidates for the position.

As a result of the agreement, all existing claims will be waived and legal proceedings will be terminated, including the request for arbitration filed by Delfin before the International Court of Arbitration of the International Chamber of Commerce on March 27.

In light of this agreement, Valoptec decided that it will withdraw the proposal submitted on April 18 for the appointment of one additional director of EssilorLuxottica. It will vote against the proposals submitted by certain institutional investors for the appointment of two additional directors, according to the release.

Advertisement

“The representative of Valoptec at the Board of EssilorLuxottica will integrate the Strategic and the Integration Committees of the Company,” according to the release.

“I’m very pleased of this outcome. The industrial rationale of the combination is even stronger when looking at all the opportunities raised during the meetings of the Integration Committee,” said Del Vecchio, executive chairman of EssilorLuxottica. “Today, respecting the equal power and the Combination Agreement, we have found a solution to better execute such strategic combination.”

Sagnières said, “With these decisions driving to a more unified company, EssilorLuxottica is well positioned to accelerate its growth in order to achieve its mission: to help people around the world to see more, be more and live life to its fullest by addressing their evolving vision needs and personal style aspirations.”

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY SHAMIR

Vision Expo East Is Upon Us

Experience the new products at Shamir Booth #LP4033, and receive a free gift.

Promoted Headlines

Headlines

Be My Eyes Raises $2.8M in Funding for App to Support Blind and Visually Impaired

It’s using a ‘purpose and profit’ business model.

mm

Published

on

SAN FRANCISCO — Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, has raised $2.8 million in funding. The investment allows the company to further develop its “purpose and profit” business model while keeping the visual support service free and unlimited for all visually impaired users, according to a press release.

The Series A round, led by Cultivation Capital, also welcomed new board members Paul Weber (Cultivation Capital) and Michael Buckley (angel investor and former vice president of global communications at Facebook). Be My Eyes has previously been backed by angels and investment funding from the likes of Singularity University, the founders of Zendesk and the LightHouse for the Blind and Visually Impaired in San Francisco.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

Be My Eyes solves a simple problem for users: It calls up a real person, on demand, to describe what’s in front of a blind user’s camera. Initially supported entirely by volunteers, Be My Eyes recently announced that it would begin partnering with companies to provide expert-level support through a new feature in the app (Specialized Help). Microsoft signed on as Be My Eyes’ first video support partner in 2018, followed by Google, Lloyds Banking Group, and Procter & Gamble, who now all provide video customer support to the BME community, which spans more than 175 countries. Companies can provide Specialized Help globally or by region, and support services are free to Be My Eyes users.

“In call centers around the world, we’ve seen the Be My Eyes software greatly reduce ticket handling times and increase satisfaction rates, from both support agents and blind or low vision callers,” says Alexander Hauerslev Jensen, chief commercial officer at Be My Eyes. “What’s more, each call that a company receives brings attention to parts of the product or service that can be designed more inclusively.”

Kyndra LoCoco, partner and programs manager at Google Accessibility, added, “The Google Disability Support team is thrilled to be building a more accessible support experience through the Be My Eyes app. It’s our hope that others join us on this journey.”

With a community of users that has doubled in size each year since 2015, Be My Eyes’ “micro-volunteering” platform “has become beloved amongst blind and sighted users alike,” according to the release.

“Fueled by inspiring stories and viral social media posts of strangers connecting across oceans to help one another, the small startup has amassed what amounts to the world’s largest global community of visually impaired people (almost 200,000), and a volunteer community many times that size (more than 3.5M).”

“Be My Eyes is a great example of how technology can help bring communities together and empower people who are blind or with low vision,” says Neil Barnett, director of inclusive hiring and accessibility at Microsoft. “By working together with Be My Eyes, their incredible sighted volunteers, and the growing community of organizations participating in the Specialized Help program, we can help more people around the world live independent lives. We are honored to be part of this vibrant community and provide support for all of their customers through our Disability Answer Desk services.”

“As we grow and age, we all need help seeing at some point,” says Be My Eyes CEO Christian Erfurt, who co-founded the company with a legally blind craftsman named Hans Jørgen Wiberg in 2014. “It’s been a pleasure to see that not only do people want to give their time to support this large population – but companies want to make their customer service offerings more accessible. For them, we’ve built a simple but beautiful tool.”

Erfurt says the corporate partnership business model was conceived so that Be My Eyes will never have to charge blind users for the service. “We believe that access to sight is a human right, and you don’t charge people for that.”

Watch a video about the service:

Continue Reading

Headlines

Alcon’s Pataday Eye Allergy Meds Get FDA Nod for Nonprescription Use

They’ll no longer be sold as prescription drugs.

mm

Published

on

The U.S. Food and Drug Administration has approved two Alcon eye allergy products for over-the-counter use through a process called a “prescription (Rx)-to-OTC switch.”

The FDA gave the OK to these medications for nonprescription use:

  • Pataday Twice Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.1%) for the temporary relief of itchy and red eyes due to pollen, ragweed, grass, animal hair or dander.
  • Pataday Once Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.2%) for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander.

“As a result of the Rx-to-OTC switch process, many products sold over-the-counter today use ingredients or dosage strengths that were available only by prescription 30 years ago,” said Karen Mahoney, MD, acting deputy director of the Office of Nonprescription Drugs in the FDA’s Center for Drug Evaluation and Research. “Approval of a wider range of nonprescription drugs has the potential to improve public health by increasing the types of drugs consumers can access and use that would otherwise only be available by prescription. This includes providing the millions of people that suffer with joint pain from arthritis daily over-the-counter access to another non-opioid treatment option.”

For a drug to switch to nonprescription status, the data provided must demonstrate that the drug is safe and effective for use in self-medication as directed in proposed labeling. The manufacturer must show that consumers can understand how to use the drug safely and effectively without the supervision of a healthcare professional.

Pataday Twice Daily Relief was first approved by the FDA in 1996 under the name Patanol as a prescription drug and was indicated for the treatment of the signs and symptoms of allergic conjunctivitis (referring to ocular redness and itching due to allergies). Pataday – now Pataday Once Daily Relief – was first approved by the FDA in 2004 as a prescription drug and was indicated for the treatment of ocular itching associated with allergic conjunctivitis. These drugs are mast cell stabilizers, which work by preventing the release of histamine and therefore prevent or control allergic disorders.

The products will be marketed in the U.S. as nonprescription drugs and will no longer be available as prescription drugs.

Continue Reading

Headlines

Optical Centers Planned for 4 Oklahoma Sam’s Club Stores As a Result of New Law

They’re expected to open within the next few months.

mm

Published

on

Optical centers will open in four Sam’s Club stores in Oklahoma City, KFOR-TV reports.

The plans follow the passage of legislation allowing optometrists to practice within retail settings. Oklahoma Gov. Kevin Stitt signed the bill into law in May 2019.

The optical centers are expected to open within the next few months. and 10 more centers are expected to open in the state by summer, according to KFOR.

Retailers are permitted to sell lenses and frames under the new legislation. But optometrists cannot be employees of retailers.

The law also does not allow retailers have control over any aspect of the eye exam.

The Oklahoma Association of Optometric Physicians has stated that the new legislation “will protect Oklahoma’s vision health standards while increasing convenience for consumers.”

Read more at KFOR-TV

Continue Reading

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular